Title : An update on acalabrutinib to treat chronic lymphocytic leukemia.

Pub. Date : 2021 Jul

PMID : 34268530






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Acalabrutinib is approved as monotherapy in the R/R or TN setting, and in the TN setting can be combined with the anti-CD20 monoclonal antibody obinutuzumab. acalabrutinib keratin 20 Homo sapiens